case_images: PMC4743131_01
case_images: QLQ-C30 Functional scales (a) and combined symptoms score (b)
case_images: 40364_2016_56_Fig1_HTML.jpg
case_images: PMC4743131_01_40364_2016_56_Fig1_HTML.jpg
case_images: Fig1
case_images: Symptoms and quality of life were assessed every 4 weeks by EORTC QLQ-C30 (Fig. 1a and b), BFI (Fig. 2), MPN-SAF (Fig. 3), and
case_images: MPN-SAF
case_images: 40364_2016_56_Fig3_HTML.jpg
case_images: PMC4743131_01_40364_2016_56_Fig3_HTML.jpg
case_images: Fig3
case_images: Skin rash prior to therapy with Ruxolitinib (a) and 24 weeks post therapy (b)
case_images: 40364_2016_56_Fig4_HTML.jpg
case_images: PMC4743131_01_40364_2016_56_Fig4_HTML.jpg
case_images: Fig4
case_images: Flushing resolved and cutaneous manifestations markedly improved (Fig. 4a and b).